Published Research and Presentations

Abstract TPS385: DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer

DASL-HiCaP

ASCO GU 2021 - Virtual Meeting

13/02/2020

Tamim Niazi, MD

Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial.

ENZAMET

ESMO 2019 Congress Poster Discussion

29/09/2019

Professor Martin Stockler

Primary Efficacy Analysis Results From The SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double blind phase III trial led by the MRC CTU at UCL.

SORCE

ESMO 2019 Congress

28/09/2019

Professor Tim Eisen on behalf of the SORCE Trial Management Group

Overall survival (OS) Results of a Phase III Randomized Trial of Standard of Care Therapy with or without enzalutamide for a Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP –led International Co-operative Group Trial

ENZAMET

MOGA ASM

16/08/2019

Professor Ian D. Davies

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial

ENZAMET

ASCO Plenary

02/06/2019

Professor Christopher J. Sweeney, MMBS

“Discrepancies in registry Coding for Penile cancer” and “The significance of demographic location in survival outcomes”.

Other

USANZ ASM

14/02/2019

Dr Simeon Ngweso – Villas Marshall Prize Winner, Penile cancer in Western Australia

TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

TheraP

ASCO GU

14/02/2019

An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP 1302)

P3BEP

ASCO GU

14/02/2019

Crossing the paediatric and adult hospital divide: An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

P3BEP

3rd AYA congress

04/12/2018

Walker et al.

An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor risk metastatic germ cell tumours: P3BEP (ANZUP 1302)

P3BEP

American Society of Clinical Oncology – Genitourinary Symposium

01/06/2018

Namrata Nayar, et al.